25
Funding Op*ons for Life Science Companies January 21, 2014

Funding options - Life Science Fast Track

Embed Size (px)

DESCRIPTION

From the life science venture fast track: http://www.thecapitalnetwork.org/programs/life-science-venture-fast-track/

Citation preview

Page 1: Funding options - Life Science Fast Track

Funding  Op*ons  for  Life  Science  Companies  

January 21, 2014

Page 2: Funding options - Life Science Fast Track

Funding  the  Company  

Assuming  you  plan  to  be    a  “high  growth”  company…  

What  are  your  funding  op*ons?  

Page 3: Funding options - Life Science Fast Track

Entrepreneurship  comes  in  many  types      

3

NORMAL  GROWTH  COMPANY  

HIGH  GROWTH  COMPANY  

EXTREME  HIGH  GROWTH  COMPANY  

SOCIAL  VENTURE  COMPANY  

•  Includes all service businesses

•  Exploiting a local market need

•  Team has ‘great jobs’

•  Growth by adding resources one by one

•  Exit will be based on value of cash flow (mature biz.)

•  Growth profile ultra-scalable

•  Team focus is exit •  Revenue $40M+

with lots of room for growth (5 yr.)

•  Based on $20M+ investment

•  Exit targeted to IPO or by ‘large’ M&A event

•  Goal is to fulfill a social need

•  Has mission orientation

•  Team needs to support mission

•  Growth profile often one resource at a time

•  Exit …much harder to find fit

•  Company can grow fast (on-line) or has a scalable system

•  Team often motivated by exit

•  $10m revenue in 5 yrs & market size allows significant additional growth

•  Capital efficient total investment$2-4M

•  Exit by M&A

Page 4: Funding options - Life Science Fast Track

Close  Up:  Extreme  High  Growth  vs  High  Growth  

4  

Capital Needs

Time

High Risk

Low Risk

Formal Venture Capital

M&A or IPO

Crystallize Ideas

Demonstrate Product

Early Scaling Growth

Sustained Growth

Angel Group (or Micro-cap) Syndication

Angels or Accelerators or Micro-cap

funds Angels or Accelerators or Micro-cap

funds Business Angels

Market Entry

M&A

Later VC Rounds

Extreme High Growth High Growth

Friends, Family & Founders

Friends, Family & Founders

Page 5: Funding options - Life Science Fast Track

High  Growth  Company  Characteris*cs  •  Disrup*ve  Innova*on  with  Strong  value  proposi*on  

–  Correla*on  between  Large  Unmet  Need  :  Solu*on  

•  High  Margin  Product  (Ra*o  of  Revenue  :  COGS)    –  Some*mes  Massive  Volume  Products  where  innova*on  is  incremental  

•  High  Rate  of  Revenue  Growth  over  sustained  period    •  Scalable  (Fixed  cost  is  a  low  percent  of  Revenue)    

•  No  major  barriers  to  con*nued  growth  (ex.  blocking  IP;  geography;  regulatory)    

•  Repeatable  sales  and  distribu*on  model  with  many  credit  worthy  customers    

•  Large  Total  Addressable  Market  (TAM)    

•  Defensible  innova*on  able  to  withstand  compe**on  and  changing  condi*ons    

•  [Capital  efficient]  

5  

Page 6: Funding options - Life Science Fast Track

Return  on  Equity  Return  on  Debt  Income   High  Return  

NON  PROFIT  ORGANIZATION  

Capital  Source  View  

6  

Debt- Pay it back Fixed Amounts

Equity – Ownership stake % of Future Value

Charity  $$  

Impact  /  Tax  Write  off  

NORMAL  GROWTH  COMPANY  

HIGH  GROWTH  

(COMPANY)  

EXTREME  HIGH  GROWTH  (COMPANY)  

Risk / Return

SOCIAL  VENTURE  COMPANY  

Page 7: Funding options - Life Science Fast Track

Match  Funding  Sources  

7  

NORMAL  GROWTH  COMPANY  

HIGH  GROWTH  COMPANY  

EXTREME  HIGH  GROWTH  COMPANY  

SOCIAL  VENTURE  COMPANY  

•  Friends family, founders

•  Debt Bank and other

•  (Future) Crowd funding (portal style)

Early on •  Accelerators •  Individual Angels •  Micro Cap VCs •  Seed from VC Later stages •  Venture Funds •  Strategic VCs •  Angel

Syndication

•  Friends family, founders

•  Charity$$ •  Crowds (Kick-

starter) •  Impact Angels •  (Future)

Crowd funding (portal style)

•  Angels •  Angel Groups •  Angel Group

Syndication •  Angel List •  Micro-cap Funds •  (Future) Crowd

funding (portal style)

•  Increasingly Strategic Corporate VCs

Page 8: Funding options - Life Science Fast Track

Non-­‐Equity  Sources  •  Accelerators  (some)  

•  Kickstarter  type  dona5ons  

•  Pre-­‐orders  from  end-­‐customers  •  Credit  from  vendors  

•  Strategic  VCs  •  Strategic  NREs  •  Distribu5on  Contracts  

Common  Theme:    Providing  early  cash  in  exchange  for  a  beHer  commercial  opportunity    

8  

Page 9: Funding options - Life Science Fast Track

Equity  Sources  •  Accelerators  (some)  

•  Friends  &  Family  

Common  Theme:  Suppor5ng  success  of  the  entrepreneur;  business  terms  vary  

•  Portal  Funding  

•  Early  Angels  •  Super  Angels  

•  Angel  Groups  

•  Micro  VC  

•  Tradi5onal  VC  (1st  Round)  

Common  Theme:  All  are  looking  for  

–  sale  (or  IPO)  of  the  Company  at  4-­‐10  x  original  investment  

–  Capital  gains  treatment  on  all  sale  proceeds  –  Preferen5al  treatment  on  subop5mal  exit  versus  the  founders  

9  

Page 10: Funding options - Life Science Fast Track

Sources  of  Equity  Capital  Must  have  exits  for  equity  model  to  work!!  

–  2011  US  IPOs  -­‐  $36B  –  2011  US  M&A  -­‐  $57B    –  2011  US  Private  Equity  -­‐$35B  

•  Exit  sources  extremely  variable  …  health  of  economy  •  All  exits:  indica*ve  of  future  cash  flow  or  market  control    

Idea  Stage    • Friends    family,  founders  

• Grants  • Crowds  (Kick-­‐  starter)  

Demonstrate  Product  &  Market  Interest    • Accelerators  • Individual  Angels  • Angel  Groups  • Accelerators  • Micro  Cap  VCs  

Market  Entry  &  Early  Growth  •   Crowdfunding  (portal  style)  •   Angel  Groups  •   Angel  Group  SyndicaSon  •   Angel  List  •   Micro-­‐cap  Funds  

Early  Scaling  Growth  •  Most  Venture  Funds  

•  Angel  SyndicaSon  

Repeatable  Growth  • Most  Venture  Funds  

• Strategic  VCs  • Angel  SyndicaSon  

• Private  Equity    

Page 11: Funding options - Life Science Fast Track

High  Growth  Capital  by  Stage  &Amount  

11  

Venture Stage

Investment Size

Friends & Family

Vendors

Angels

Traditional VC

Angel Groups

Corporate Venturing

Grants

Customers

Crowdfunding

Portal Funding

AngelList

Micro VC

Equipment Financing

Founder

Page 12: Funding options - Life Science Fast Track

Capital  Sources:  Size  &  Cost  

Investment Size

Investment “Cost”

Traditional VC

Micro VC

Equipment Financing

Angel Groups Angels

AngelList

Corporate / Strategic Venture

Customers

Portal Funding

Vendors

Founder Friends & Family

Crowdfunding

Grants

Venture Debt Bank

Loans

Personal Loans

Private Equity

Page 13: Funding options - Life Science Fast Track

So  What  is  Equity  Anyway?  

•  Stock  =  right  to  residual  economic  interests  upon  sale/liquida*on  +  stockholder  vo*ng  rights  (usually  limited  to  Board  of  Directors  and  Sale  of  the  Company)  

•  Preferred  Stock  =  right  to  be  paid  before  Common  Stock  Par*cipa*ng  =  original  investment  PLUS  a  pro  rata  share  of  remainder  Non-­‐Par*cipa*ng  =  original  investment  OR  a  pro  rata  share  

•  Common  Stock  =  whatever  is  lep  aper  all  other  creditors  and  preferred  stockholders  are  paid  

•  Dividend  =  a  right  to  an  addi*onal  amount  upon  liquida*on  measured  as  a  func*on  of  *me  x  percentage  of  original  investment  .  Ex.  6.0%  per  annum  

•  OpSons  /  Warrants  =  Contracts  allowing  holder  to  purchase  an  amount  of  stock  in  the  future  at  a  pre-­‐determined  price  

•  Control  Rights  =  Statutory  and  Contractual  

13  

Page 14: Funding options - Life Science Fast Track

Equity  Type  Comparisons  

14  

Solo  Angel   Super  Angel   Angel  Group   MicroVC   VC  

Valua*ons   High  rela*ve  to  stage  

High  rela*ve  to  stage  

Low  rela*ve  to  stage  

Low  rela*ve  to  stage  

Medium  

Type  -­‐  Likely  (less  likely)  

Common  (Warrants)  

Conv  Note  (Preferred)  

Preferred  (Conv  Note)  

Preferred  (Conv  Note)  

Preferred  

Board  Seat   Maybe   1  or  none   1-­‐2  of  5  +/-­‐  Observer  

1  of  5  +/-­‐  Observer  

1-­‐2  of  5  +/-­‐  Observer  

Audited  Financials  

No   No   No  (reviewed)   Yes   Yes  

Nega*ve  Covenants  

No   Some*mes   Yes   Yes   Yes  

Preemp*ve  Rights  

No   Some*mes   Yes   Yes   Yes  

Ver*cal  Exper*se  

Some*mes   Rarely   Some   Usually   Always  

Page 15: Funding options - Life Science Fast Track

Equity  Type  Comparisons  

15  

Solo  Angel   Super  Angel   Angel  Group   MicroVC   VC  

Exit  Horizon  (from  $  in)  

7  years   5  years   4  years   5  -­‐7  years   4-­‐5  years  

Exit  Range   $20m+   $40m+   $50m+   $100m+   $250m+  

Page 16: Funding options - Life Science Fast Track

Structure  of  an  Equity  Deal  •  Company  and  Investors  agree  on  a  “pre-­‐money  valua*on”  (PM)  which  leads  to  a  price  per  share  

•  Investors  put  in  $X  •  Investors  then  own:  X  /  (X  +  PM)  of  the  company  

Example:  PM  =  $1M  X  =  $0.5M  Investors  own  0.5/1.5  =  33%  

Remember:  New  issuance  NOT  transfer  16  

Page 17: Funding options - Life Science Fast Track

Understand  the  Funding  Path  

•  We’re  talking  about  1st  funding  here  •  What  is  the  probable  complete  funding  picture?  

– This  is  only  funding  – Another  small  round  then  probable  small  exit  – Big  money  needed  before  exit  

•  Each  funding  event  should  occur  at  an  “inflec5on  point”  – Hopefully  at  a  point  where  risk  is  removed  –  Increased  PM  =  so-­‐called  “up  round”  

17  

Page 18: Funding options - Life Science Fast Track

Understand  the  Funding  Path,  cont.  

•  What  if  things  aren’t  going  so  well?  – Flat  or  decreased  PM  =  so-­‐called  “down  round”  

•  More  money  coming  in  without  increased  PM  means  everyone  gets  diluted,  but…  

•  Depending  on  anS-­‐diluSon  provision  entrepreneur  may  carry  more  burden  than  the  investors  

18  

Page 19: Funding options - Life Science Fast Track

What  about  Conver*ble  Debt?  

•  Many  seed-­‐stage  companies  use  an  instrument  called  Conver5ble  Debt.  Huh?  

•  Conver5ble  debt  is  not  tradi5onal  bank  debt  •  Converts  exist  for  two  major  reasons  

–  Investors  and  Entrepreneurs  find  it  hard  to  agree  on  a  PM  valua5on  

– Some5mes  quicker  and  cheaper  to  document  than  equity  deals  (but  not  really)  

19  

Page 20: Funding options - Life Science Fast Track

Conver*ble  Debt  provides  Op*onality  

•  ConverSble  Debt  =  unsecured  debt  obliga*on  of  the  Company  that  may  be  converted  into  equity  of  the  Company.    

•  Conversion  Trigger  =  Qualified  Financing  usually  at  some  minimum  amount  of  funds  (ex.  $500,000)  

•  If  Notes  stays  as  Debt  =  Get  back  principal  and  interest  ahead  of  other  equity  (behind  other  creditors  typically)  

•  If  Notes  Convert    =  Convert  amount  of  debt  and  interest  into  equity  at  the  valua*on  in  the  next  round  

•    aper  applica*on  of  a  Discount  (open  5  –  20%)  •    subject  to  a  maximum  valua*on  amount  (the  “Cap”)  

20  

Page 21: Funding options - Life Science Fast Track

Basic  Structure  of  Conver*ble  Debt  •  Investor  loans  $  to  Company  an5cipa5ng  another  round  of  funding  •  Investment  accrues  small  interest    •  When  the  funding  occurs,  investment  +  interest  convert  to  equity,  

usually  at  a  discount  (5-­‐20%  typically)  

Example:  •  Investors  loan  $200K  to  Company    •  20%  discount  •  As  of  conversion,  interest  of  $10k  has  accrued  •  Next  Round  PM  =  $2m  •  Conversion  Amount  =  1/(1  -­‐  0.2)*  $210k    =  $262,500  

At  Conversion,  Noteholders  receive  262.5K  /  (PM  +  262.5K  +  New  Money)  

21  

Page 22: Funding options - Life Science Fast Track

Conver*ble  Debt  –  Complica*ons!  

•  When  does  the  debt  convert?  •  What  happens  if  PM  of  next  round  is  huge?  

•  Does  the  investor  have  any  say  in  things?  •  What  if  there  is  an  equity  investment  that  doesn’t  trigger  conversion?  

•  What  happens  if  it  never  converts?  

•  What  happens  if  Company  gets  bought?  

22  

Page 23: Funding options - Life Science Fast Track

Conver*ble  Debt  –  Solu*ons?  

•  Caps  and  Floors  – May  defeat  purpose  with  signaling  

•  Default  conversion  price  and  security  at  maturity  

•  Quick  sale  preferences  (ex.  2x)  •  Governance  provisions  •  Careful  agenSon  to  conversion  condiSons  

23  

Page 24: Funding options - Life Science Fast Track

Conver*ble  Debt  –  Worse  than  Equity?  

•  MulSple  liquidaSon  preference  (circa  2008)  –  Ex.  $500k  of  Notes  with  cap  at  $2m  PM  –  Next  Round  at  $6m  PM  –  Issue  Noteholders  3x  number  of  shares  –  3x  shares  equals  3x  liquidaSon  preference!!  

•  Without  a  floor,  effecSvely  Full  Ratchet  AnS-­‐diluSon  

•  Preference  Overhang  –  In  prior  example  Noteholders  bought  $262,500  of  preference  for  

$200,000.      –  All  other  Series  A  Holders  bought  1:1  preference  

•  Not  Just  a  Price  Adjustment  

24  

Page 25: Funding options - Life Science Fast Track

www.TheCapitalNetwork.org